SS Innovations International, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2024-09-30; filed 2024-11-14.
0001213900-24-097890
Unregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresCurrent report: 10-Q
Period ended 2025-03-31; filed 2025-05-14.
0001213900-25-043327
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 4 previous paragraphs and 9 current paragraphs.
2 unchanged; 1 reworded; 6 added; 1 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (6)
Current report
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Current report
Dr. Sudhir Srivastava, our Chairman and Chief Executive Officer, through Sushruta Pvt. Ltd. (“Sushruta”), his holding Company, provided the Company with $2,000,000 in financing on December 4, 2024, $5,000,000 in financing on January 3, 2025, $10,000,000 in financing on January 20, 2025, $5,000,000 in financing on January 30, 2025 and $8,000,000 in financing on March 19. 2025. Each tranche of financing provided by Dr. Srivastava was evidenced by a one-year convertible promissory note (collectively, the “One-Year Notes”). The One-Year Notes bore interest at the rate of seven percent (7%) per annum, which accrued and was due at maturity. The One-Year Notes were convertible at the option of the holder into shares of our common stock at a conversion price of $1.38 per share, subject to adjustment for stock splits, stock dividends and similar recapitalization events. As of March 31, 2025, all $30,000,000 in principal amount of One-Year Notes, together with $164,548 in interest thereon, were converted by Sushruta into 21,858,368 shares of our common stock.
Current report
Item 3. Defaults Upon Senior Securities.
Removed paragraphs (1)
Previous report
In September 2024, the Company issued 125,000 shares of common stock in a private transaction to five doctors/proctors in India in consideration of their ongoing contributions for providing surgeon training support and proctoring surgeries on our recently installed SSi Mantra Surgical Robotic Systems.
Reworded paragraphs (1)
Previous wording
The foregoing shares of common stock were issued in pursuant to the exemption from registration afforded by Section 4(a)(2) under the Securities Act of 1933, as amended.
Current wording
The foregoing securities were issued in accordance with the exemption from registration afforded by Section 4(a)(2) of under the Securities Act of 1933, as amended.